Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Eur J Obstet Gynecol Reprod Biol. 2001 Mar;95(1):119-26.

Nitrofurantoin and congenital abnormalities.

Author information

  • 1Department of Human Genetics and Teratology, Foundation for the Community Control of Hereditary Diseases, National Centre for Epidemiology, Torokvesz Lejto 32, 1026, Budapest, Hungary. czeizel@interware.hu

Abstract

OBJECTIVE:

To study human teratogenic potential of oral nitrofurantoin treatment during pregnancy.

MATERIALS AND METHODS:

Pair analysis of cases with congenital abnormalities and matched population controls in the population-based dataset of the Hungarian Case-Control Surveillance of Congenital Abnormalities, 1980-1996.

RESULTS:

Of 38,151 pregnant women who had newborn infants without any congenital abnormalities (population control group), 774 (3.4%); of 22,865 case pregnant women who had newborns or fetuses with congenital abnormalities, 1079 (2.8%) and of 812 pregnant women who had newborns or fetuses with Down's syndrome (patient controls), 23 (2.8%) pregnant women were treated with nitrofurantoin. The above differences between population controls and cases may be connected with recall bias, because the case-control pair analysis did not indicate a teratogenic potential of nitrofurantoin use during the second and the third months of gestation, i.e. in the critical period for major congenital abnormalities.

CONCLUSION:

Treatment with nitrofurantoin during pregnancy does not present detectable teratogenic risk to the fetus.

PMID:
11267733
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk